metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus Standard of Care (SoC)
	cemiplimab vs. Standard of Care (SoC)	1	none	inconclusive results for: DOR; AE leading to death (grade 5); AE leading to treatment discontinuation (any grade); Colitis TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Hepatitis TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Increase AST TRAE (grade 3-4); Increased ALT TRAE (grade 3-4); Maculopapular rash TRAE (grade 3-4); Nephritis TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Rash TRAE (grade 3-4); hepatitis (Autoimmune) AE (grade 3-4); Acute kidney injury AE (grade 3-4); Alopecia AE (grade 3-4); Arthralgia AE (grade 3-4); Asthenia AE (grade 3-4); Back pain AE (grade 3-4); Blood creatinine increased AE (grade 3-4); Constipation AE (grade 3-4); Decreased appetite AE (grade 3-4); Diarrhoea AE (grade 3-4); Dyspnoea AE (grade 3-4); Fatigue AE (grade 3-4); Febrile neutropenia AE (grade 3-4); Hypertension AE (grade 3-4); Increase AST AE (grade 3-4); Increased ALT AE (grade 3-4); Increased Lipase Level AE (grade 3-4); myocarditis AE (grade 3-4); Nausea AE (grade 3-4); Pancytopenia (AE grade 3-4); Peripheral neuropathy AE (grade 3-4); Peripheral sensory neuropathy AE (grade 3-4); Pneumonia AE (grade 3-4); Pneumonitis AE (grade 3-4); Rash AE (grade 3-4); Rash maculopapular AE (grade 3-4); Stomatitis AE (grade 3-4); Vomiting AE (grade 3-4); Weight decreased AE (grade 3-4)	statistically conclusive 32 % decrease in deaths (OS) but the degree if certainty is unassessable statistically conclusive 41 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable statistically conclusive 2.2-fold increase in objective responses (ORR) but the degree if certainty is unassessable suggested 82 % decrease in AE (any grade) but the degree if certainty is unassessable suggested 81 % decrease in AE (grade 3-4) but the degree if certainty is unassessable suggested 97 % decrease in Anaemia AE (grade 3-4) but the degree if certainty is unassessable suggested 90 % decrease in Leucopenia AE (grade 3-4) but the degree if certainty is unassessable suggested 95 % decrease in Neutropenia AE (grade 3-4) but the degree if certainty is unassessable suggested 98 % decrease in Thrombocytopenia AE (grade 3-4) but the degree if certainty is unassessable	-
mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	cemiplimab vs. Standard of Care (SoC)	1	none	inconclusive results for: DOR	suggested 43 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 46 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 2.5-fold increase in objective responses (ORR) but the degree if certainty is unassessable	-
mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb
non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population
non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)
squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population